Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Expanding US operations to address the increased demand for API development and manufacturing
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab
Subscribe To Our Newsletter & Stay Updated
